---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-014773"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:49:24.708841+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xilio Q3 net loss $14.0M; Phase 1C vilastobart + atezolizumab shows partial responses in cold tumors

## Summary
- Cash $61.3M as of Sept 30, 2024; cash runway through Q2 2025.
- Phase 1C: 2 unconfirmed PRs (MSS CRC with liver lesion resolution, ampullary carcinoma); no Grade 4/5 treatment-related AEs.
- RP2D selected: vilastobart 100 mg Q6W + atezolizumab 1200 mg Q3W; Phase 2 enrolling MSS CRC.
- Initial Phase 2 data for vilastobart combo in ~20 MSS CRC patients expected Q4 2024; ~40 total by Q1 2025.
- License revenue $2.3M from Gilead agreement; net loss $14.0M vs $16.7M YoY.

## SEC filing metadata
- accession: 0001558370-24-014773
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837024014773/0001558370-24-014773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837024014773/xlo-20241107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-014773
- JSON: https://secwatch.observer/filing/0001558370-24-014773.json
- Plain text: https://secwatch.observer/filing/0001558370-24-014773.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.